Navigation Links
FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
Date:7/14/2008

Data Provides Further Information on AVANDIA as a Safe and Effective

Treatment Option for Appropriate Type 2 Diabetes Patients

PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announces today that the U.S. Food and Drug Administration (FDA) updated the prescribing information for AVANDIA(R) (rosiglitazone maleate) to include clinical findings from A Diabetes Outcome Progression Trial (ADOPT), a 4- to- 6 year head-to-head study of AVANDIA versus metformin and glyburide monotherapy in recently diagnosed type 2 diabetes patients. The percentage of patients with inadequate glucose control at five years was 34 percent with glyburide, 21 percent with metformin and only 15 percent with AVANDIA. The difference between AVANDIA and the comparators was statistically significant.

"GSK is pleased that the FDA has approved inclusion of the results from ADOPT, an important clinical trial that provides substantial long-term efficacy and safety data on AVANDIA compared to metformin and sulfonylurea," said Alexander R. Cobitz, MD, PhD, Senior Director, Metabolism, Clinical Development and Medical Affairs, GlaxoSmithKline. "As demonstrated in this study, patients treated with AVANDIA achieved greater sustained glycemic control. Better glycemic control has been proven to reduce risks of serious complications associated with type 2 diabetes including blindness, loss of limbs and kidney failure."

Study Design

ADOPT was a large, international, multi-center, randomized, double-blind, parallel-group study involving 4,351 people, aged 30-75 years who were recently diagnosed with type 2 diabetes (less than or equal to 3 years) from more than 400 sites throughout North America and Europe. ADOPT, conducted over a period of 4 to 6 years, assessed the cumulative incidence of monotherapy failure at five years with AVANDIA, metformin, glyburide, as defined by consecutive fasting plasma glucose (FPG) >180 mg/dL.

Patients
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
6. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
7. BioCryst Updates Peramivir Clinical Development Plan
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
10. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
11. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: CUR) announced ... at Emory University, presented long-term follow up data on ... cells in the treatment of amyotrophic lateral sclerosis (ALS ... occurred at the Annual Symposium on ALS of the ... on Friday, and was not open to the public, ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a ... solutions for medical and surgical procedures, among other ... deal with Munich -based Brainlab ... ® Navigation. This agreement applies to the ... cross-disciplinary U.S. sales and all distribution outside the ...
(Date:9/22/2014)... , Sept. 22, 2014  Inovio Pharmaceuticals, Inc. ... has initiated a phase I clinical trial in ... the safety, tolerability, and immunogenicity of INO-3106. This ... causes most aerodigestive cancers. Aerodigestive cancers ... cords, and parts of the esophagus and windpipe. ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... , , DALLAS , February ... and Central Labs events present Advanced,Biomarker Strategies in Oncology Drug Development. ... from February 4-5, 2010 . This,event is FREE for executives ... This two-day program focuses exclusively on the latest developments in,oncology biomarkers. ...
... RESEARCH TRIANGLE PARK, N.C. , Jan. 29 ... the U.S. Food and Drug Administration has approved ... in patients ages 13 years and older with primary generalized ... XR is approved for partial onset seizures ...
Cached Medicine Technology:MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 2MarketsandMarkets Partners With IIR USA for Their Event 'Advanced Biomarker Strategies in Oncology Drug Development' 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 2FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 3FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 4FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 5FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 6FDA Approves Once-A-Day Lamictal(R)XR(TM) as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures 7
(Date:9/22/2014)... (PRWEB) September 22, 2014 The New ... Department of Surgery at the Icahn School of Medicine ... New York Group for Plastic Surgery gives residents of ... to a team of world-renowned plastic surgeons performing innovative ... Andrew Salzberg, MD, who led NYGPS, was named the ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 WHO: ... center and customer service solutions. , WHAT: The ... focused on customer care for the connected consumer. ... continue to offer new challenges and opportunities for ... helping attendees identify best practices, network and learn ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... ARBOR, Mich. Many parents whose kids participate in ... concussion education, but that,s not enough to ensure parents ... new University of Michigan C.S. Mott Children,s Hospital National ... half of the 912 parents of middle and high ... concussion education: , , 23% have read a ...
(Date:9/22/2014)... (Sept. 22, 2014) The success of a colonoscopy ... bowel prep often resulting in missed precancerous lesions, according ... Task force on Colorectal Cancer. Additionally, poor bowel cleansing ... procedures. Up to 20 to 25 percent of all ... , "When prescribing bowel preparation for their patients, ...
Breaking Medicine News(10 mins):Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:Some concussion education more useful than others, parents say 2Health News:Good bowel cleansing is key for high-quality colonoscopy 2Health News:Good bowel cleansing is key for high-quality colonoscopy 3
... Something rotten never smelled so sweet. This is ... Laboratory (CSHL) are telling one another as they discuss a new ... that hydrogen sulfide (H2S) the flammable, highly toxic gas that ... and sewers plays an important role in the regulation of ...
... lifestyle habits relate to the risk of certain cancers (e.g., ... authors estimate the proportion of cancer in the population associated ... find that smoking has, by far, the largest effect on ... the UK attributable to tobacco use. A poor diet ...
... their arms asymmetrically -- one arm swings less than ... easily detected early when drugs and other interventions may ... who used inexpensive accelerometers on the arms of Parkinson,s ... known for some time that people with Parkinson,s disease ...
... York, NY, December 13, 2011JDRF-funded researchers have begun enrolling ... study, to test whether metformina drug commonly used to treat ... cardiovascular complications in people with T1D. The REMOVAL study ... multi-center, international trial that will study 500 patients with T1D ...
... Ph.D., Associate Professor of Surgery at Thomas Jefferson University ... and Related Cancers Center , and Mon-Li Chu, ... Dermatology and Cutaneous Biology , were awarded $200,000 from ... Concept Program for their breakthrough work on a ...
... or a bed has to deal with numerous complications. ... physicians call them. Bony prominences, such as the sacrum, ... can lead to tissue necrosis. Damage can extend into ... The ulcers are entryways for germs, which can trigger ...
Cached Medicine News:Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 2Health News:Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding 3Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 2Health News:Increased arm swing asymmetry is early sign of Parkinson's disease 3Health News:JDRF-funded study seeks to reduce cardiovascular risk 2Health News:Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research 2Health News:Thomas Jefferson University receives Science Center's QED Award for pancreatic cancer research 3Health News:Lying and sitting more comfortably 2
... 150 watt halogen light ... , ,SOLOS Endoscopy shares ... patient with the highest quality ... research and development of advanced ...
... first for Linvatec! The EnVision Autoclavable ... and proprietary technology to ensure true ... Shockflex prism system gives our customers ... their investment. With an integrated multi-specialty ...
... surgery is founded on superior medical video ... 3-Chip cameras, 1-Chip cameras, Light sources, Couplers ... demanding needs., ,Superior resolution and color ... 3-Chip cameras, and are the benchmark by ...
... System provides easy-to-use features, auto iris, white ... camera head construction is based on Solos ... 1-Chip Camera System, Domestic (GS 9960-NTSC) includes: ... with power cord and video cables , ...
Medicine Products: